For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
GLUT1 mRNA and Protein Expression in Ovarian Borderline Tumors and CancerRudlowski C.a · Moser M.b · Becker A.J.c · Rath W.d · Buttner R.e · Schroder W.f · Schurmann A.g
aDepartment of Gynecology and Obstetrics, University Hospital Heidelberg, Heidelberg, bDepartment of Molecular Medicine, Max Planck Institute for Biochemistry, Martinsried, cDepartment of Neuropathology, University of Bonn Medical Center, Bonn, dDepartment of Gynecology and Obstetrics, University Hospital Aachen, Aachen, eInstitute of Pathology, University of Bonn Medical Center, Bonn, fCentral Hospital, Bremen, gGerman Institute of Human Nutrition, Potsdam-Rehbrücke, Germany
Objectives: Increased glucose uptake and utilization is a major feature of malignant tumors. Recent studies suggest that the key mechanism of enhanced glucose metabolism in carcinoma cells involves the overexpression of transmembrane glucose transporter proteins (GLUTs). The aim of the present study was to analyze the expression of different GLUT isoforms (GLUT1–4) and to investigate whether alterations in their expression pattern accompany the malignant transformation and progression of ovarian cancer. Methods: Tumor tissue of 94 patients suffering from primary ovarian cancer (n = 78) or borderline tumors (n = 16) and tissue from 16 patients with benign ovarian changes were examined in this study. Immunohistochemistry was performed using polyclonal GLUT1–4 antibodies. GLUT1 protein expression was quantified by Western blot analysis. GLUT1 mRNA expression was analyzed by mRNA in situ hybridization. Results: All of the invasive carcinomas were positive for GLUT1. In contrast, GLUT1 expression was moderate in borderline tumors and weak to negative in all benign ovarian neoplasms. High GLUT1 mRNA levels were observed only in ovarian cancer. The intensity of GLUT1 expression in malignant ovarian neoplasms was associated neither with tumor characteristics nor with patient survival. Only GLUT3 revealed weak but homogeneous expression in human ovarian cancer as well as in benign ovarian tumors. GLUT2 and GLUT4 showed no expression in ovarian tissue. Conclusions: GLUT1 mRNA and protein were found to be expressed specifically in primary ovarian cancer. The close relationship between GLUT1 mRNA and protein expression points towards the potential relevance of GLUT1 as a diagnostic tool and therapeutic target in ovarian cancer.
© 2004 S. Karger AG, Basel